Cardinal Health Inc

CAH remains in Stage 3 distribution despite its long-term uptrend. Medium-term structure is bearish, reinforced by the Double Top and repeated failures at the 9/21 EMAs. An active Lockout Rally triggers a short-term bullish timing override but conflicts with the bearish medium-term bias. Execution should be deferred: trim into the 9/21 EMA resistance zone on rejection.

• ↑Q3 revenue $61B (+11% YoY), driven by pharmaceutical and specialty demand.
• ↑Raised full-year EPS target to $10.70–$10.80, signaling ~30% growth.
• ↓Valuation stretched vs. peers on P/E multiple, risking correction.